TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11848031

Group type: EXPERIMENTAL
Intervention: Immunotherapy using allogenic leukocytes from the partner
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 9394162

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of glucose, amino acids, and emulsion enriched in essential fatty acids (EFAs)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Non-EFAs treated cases (control group)
Number of subjects: 30
Study: 7967861

Group type: EXPERIMENTAL
Intervention: Practice guideline for early transfer of low-risk patients with CHF 24 hours after hospital admission, supported by personalized reminders.
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Practice guideline implementation
Number of subjects: 90
Study: 3631497

Group type: EXPERIMENTAL
Intervention: Anesthesia with enflurane
Number of subjects: 50

Group type: COMPARATOR
Intervention: Balanced anesthesia with enflurane and fentanyl
Number of subjects: 50
Study: 30843712

Group type: EXPERIMENTAL
Intervention: Negative evaluative conditioning (EC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral evaluative conditioning (EC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Negative evaluative conditioning (EC) with focus on feelings
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Negative evaluative conditioning (EC) with focus on knowledge
Number of subjects: 0
Study: 27545848

Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every other week
Number of subjects: 0
Study: 25692479

Group type: EXPERIMENTAL
Intervention: TiZr implants
Number of subjects: 10

Group type: COMPARATOR
Intervention: cpTi implants
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: TiZr and cpTi implants
Number of subjects: 10
Study: 24971004

Group type: EXPERIMENTAL
Intervention: Prolonged-release melatonin (PRM) 2 mg nightly for 24 weeks
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Prolonged-release melatonin (PRM) 2 mg nightly for 24 weeks in comorbid insomnia subgroup
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 23060506

Group type: EXPERIMENTAL
Intervention: TMC+RABORAL V‐RG
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: RABORAL V‐RG
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: chitosan+RABORAL V‐RG
Number of subjects: 40

Group type: COMPARATOR
Intervention: no vaccine
Number of subjects: 40
Study: 18668682

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg twice daily for 10 weeks
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Metronidazole 500 mg twice daily for 10 weeks
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 17352021

Group type: EXPERIMENTAL
Intervention: Transnasal EGD (TN‐EGD)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Transoral EGD (TO‐EGD)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Conventional EGD (C‐EGD)
Number of subjects: 160
Study: 15129926

Group type: EXPERIMENTAL
Intervention: 1000 mg/d of supplemental calcium
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 23
Study: 11794170

Group type: EXPERIMENTAL
Intervention: Additional localized dose of 16 Gy radiation (given in eight fractions by external electron beam)
Number of subjects: 5318

Group type: COMPARATOR
Intervention: Standard treatment (50 Gy radiation to the whole breast)
Number of subjects: 5318

Group type: EXPERIMENTAL
Intervention: Additional localized dose of 16 Gy radiation (for patients 40 years old or younger)
Number of subjects: 5318

Group type: COMPARATOR
Intervention: Standard treatment (for patients 40 years old or younger)
Number of subjects: 5318

Group type: COMPARATOR
Intervention: Standard treatment (for patients aged 41 to 50 years)
Number of subjects: 5318
Study: 9478309

Group type: EXPERIMENTAL
Intervention: Tibolone
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 8200217

Group type: EXPERIMENTAL
Intervention: Copper T 380A (TCu 380A) IUD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Copper T 200 (TCu 200) IUD
Number of subjects: 0
Study: 2822334

Group type: EXPERIMENTAL
Intervention: labetalol
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: metoprolol
Number of subjects: 5

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 5
Study: 29614276

Group type: EXPERIMENTAL
Intervention: 1-dose misoprostol
Number of subjects: 250

Group type: COMPARATOR
Intervention: multiple-dose misoprostol
Number of subjects: 250
Study: 27450392

Group type: EXPERIMENTAL
Intervention: Valaciclovir (2 g QDS or reduced according to renal function) for 6 months
Number of subjects: 50

Group type: COMPARATOR
Intervention: No additional treatment for 6 months
Number of subjects: 50
Study: 24333108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 305
Study: 23764238

Group type: EXPERIMENTAL
Intervention: 200mg TSU-68 twice daily
Number of subjects: 103

Group type: COMPARATOR
Intervention: No medication (Control)
Number of subjects: 103
Study: 19897460

Group type: EXPERIMENTAL
Intervention: Low-workload myocardial ischaemia (p-EST) followed by maximal exercise stress test (EST-2)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Low-workload myocardial ischaemia (p-EST)
Number of subjects: 20
Study: 18548577

Group type: EXPERIMENTAL
Intervention: SMA stimulation (high-frequency rTMS over the supplementary motor area)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Sham stimulation (placebo control)
Number of subjects: 99
Study: 16970100

Group type: EXPERIMENTAL
Intervention: Modified Kangjia Recipe (KR) combined with propylthiouracil (PTU)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Propylthiouracil (PTU) alone
Number of subjects: 90
Study: 11854874

Group type: EXPERIMENTAL
Intervention: Immediate extubation (within 1 hour of surgery)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Short-term mechanical ventilation (3 hours)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Both groups (immediate extubation and mechanical ventilation)
Number of subjects: 35
Study: 10396718

Group type: EXPERIMENTAL
Intervention: 10-ml 0.125% bupivacaine administered twice daily for 4 days
Number of subjects: 50

Group type: COMPARATOR
Intervention: Saline administered twice daily for 4 days
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups received treatment
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 10-ml 0.125% bupivacaine administered
Number of subjects: 50
Study: 7551329

Group type: EXPERIMENTAL
Intervention: Ultrasonic laparoscopic coagulating shears
Number of subjects: 31

Group type: COMPARATOR
Intervention: Clipping method
Number of subjects: 31
Study: 2328177

Group type: EXPERIMENTAL
Intervention: Tubocurarine 0.4‐0.5 mg kg‐1
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pancuronium 0.07‐0.08 mg kg‐1
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Alcuronium 0.2‐0.3 mg kg‐1
Number of subjects: 30
Study: 6968184

Group type: EXPERIMENTAL
Intervention: Continuous aortic cross‐clamping
Number of subjects: 480

Group type: COMPARATOR
Intervention: Intermittent aortic cross‐clamping
Number of subjects: 480
Study: 30371552

Group type: EXPERIMENTAL
Intervention: Pure unilateral rhythmic movement therapy consisting of 12 sessions over 1 month, involving straight or circular rhythmic movements with robotic assistance.
Number of subjects: 13
Study: 27344569

Group type: EXPERIMENTAL
Intervention: Closed suction wound drainage (Group A)
Number of subjects: 56

Group type: COMPARATOR
Intervention: No tube drainage (Group B)
Number of subjects: 56
Study: 25900353

Group type: EXPERIMENTAL
Intervention: Lower levels of forced expiratory volume at 1 second (FEV1)
Number of subjects: 3811

Group type: EXPERIMENTAL
Intervention: Lower levels of forced vital capacity (FVC)
Number of subjects: 3811

Group type: COMPARATOR
Intervention: Percentage emphysema
Number of subjects: 3811
Study: 23481119

Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone agonist (leuprolide)
Number of subjects: 20
Study: 21294869

Group type: EXPERIMENTAL
Intervention: Intervention schools
Number of subjects: 3908

Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 3908
Study: 19661195

Group type: EXPERIMENTAL
Intervention: Placebo acupuncture with warm empathic interaction (Augmented)
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Placebo acupuncture with neutral interaction (Limited)
Number of subjects: 289

Group type: COMPARATOR
Intervention: Waitlist control (Waitlist)
Number of subjects: 289
Study: 17259203

Group type: EXPERIMENTAL
Intervention: Randomized controlled trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Observational studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Electronic health record
Number of subjects: 0
Study: 15357767

Group type: EXPERIMENTAL
Intervention: rAHF-PFM
Number of subjects: 111

Group type: COMPARATOR
Intervention: Prophylactic regimen adherence
Number of subjects: 111
Study: 11491421

Group type: EXPERIMENTAL
Intervention: Amprenavir 900 mg twice daily
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Amprenavir 1050 mg twice daily
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Amprenavir 1200 mg twice daily
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Amprenavir/Abacavir 900 mg twice daily (combination therapy)
Number of subjects: 62
Study: 9536859

Group type: EXPERIMENTAL
Intervention: beta-carotene (40 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: lycopene (38 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: lutein (31.2 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: beta-carotene
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: lycopene
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: lutein
Number of subjects: 12
Study: 7625111

Group type: EXPERIMENTAL
Intervention: Oral RRV-TV rotavirus vaccine with IPV
Number of subjects: 100

Group type: COMPARATOR
Intervention: Oral RRV-TV rotavirus vaccine with OPV
Number of subjects: 100
Study: 2773899

Group type: EXPERIMENTAL
Intervention: Bismuth subsalicylate (BSS) 30 ml (525 mg) q.i.d. for 21 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bismuth subsalicylate (BSS)
Number of subjects: 20
Study: 152612

Group type: EXPERIMENTAL
Intervention: 1% 6‐aminonicotinamide (6‐AN) gel
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: 1% 6‐aminonicotinamide (6‐AN)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Topical 6‐AN and oral niacinamide therapy
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Topical 6‐AN
Number of subjects: 99
Study: 29587297

Group type: EXPERIMENTAL
Intervention: Nebulized amikacin (0.2 g) treatment twice daily for 2 weeks along with intravenous antibiotic therapy
Number of subjects: 143

Group type: COMPARATOR
Intervention: Standard antibiotic therapy alone
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Nebulized amikacin treatment
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 143
Study: 27669971

Group type: EXPERIMENTAL
Intervention: Tristel Trio Wipes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PeraSafe
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cidex OPA
Number of subjects: 0
Study: 25154674

Group type: EXPERIMENTAL
Intervention: Fertility Preservation (FP) patients
Number of subjects: 138

Group type: COMPARATOR
Intervention: Infertile patients
Number of subjects: 138
Study: 22959905

Group type: EXPERIMENTAL
Intervention: DMPA-SC (104 mg administered at baseline and 12 weeks later)
Number of subjects: 15
Study: 20625123

Group type: EXPERIMENTAL
Intervention: Methylphenidate (54 mg/d)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study: 18581018

Group type: EXPERIMENTAL
Intervention: 0.6 mg/kg of rocuronium
Number of subjects: 150

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 150
Study: 15851721

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 1548
Study: 14509173

Group type: EXPERIMENTAL
Intervention: Rofecoxib
Number of subjects: 30

Group type: COMPARATOR
Intervention: Mefenamic acid
Number of subjects: 30
Study: 10595696

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 8 mg once daily (o.d.)
Number of subjects: 4000

Group type: COMPARATOR
Intervention: Placebo o.d.
Number of subjects: 4000
Study: 9092434

Group type: EXPERIMENTAL
Intervention: Ambulatory mechanical left ventricular assistance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cardiac transplantation
Number of subjects: 0
Study: 2064203

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0
Study: 7113312

Group type: EXPERIMENTAL
Intervention: Profenid (3 capsules + 1 suppositorium)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Indomethacin (3 capsules + 1 suppositorium)
Number of subjects: 38
Study: 2982491

Group type: EXPERIMENTAL
Intervention: Central IV hyperalimentation (IVH) over a 28-day period with higher caloric and protein intake for nutritionally depleted patients.
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Central IV hyperalimentation (IVH).
Number of subjects: 119
Study: 30962094

Group type: EXPERIMENTAL
Intervention: Japanese encephalitis vaccine IXIARO®
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Japanese encephalitis vaccine IXIARO® with TBE vaccination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Japanese encephalitis vaccine IXIARO® without TBE vaccination
Number of subjects: 0
Study: 28533517

Group type: EXPERIMENTAL
Intervention: 20 mg vortioxetine for 14 days
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo for 14 days
Number of subjects: 96
Study: 27225336

Group type: EXPERIMENTAL
Intervention: Dienogest
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Goserelin
Number of subjects: 198

Group type: COMPARATOR
Intervention: Non-treatment
Number of subjects: 198
Study: 24977638

Group type: EXPERIMENTAL
Intervention: Deep neuromuscular blockade
Number of subjects: 48

Group type: COMPARATOR
Intervention: Moderate neuromuscular blockade
Number of subjects: 48
Study: 22175765

Group type: EXPERIMENTAL
Intervention: Specific IgE ≥0.35 kU(A)/l for hazelnut
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: rCor a 1 spiking of the ImmunoCAP
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Specific IgE cutoff of 26 kU(A)/l
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Skin prick test (SPT) for hazelnut
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: History of accidental ingestion leading to an allergic reaction to hazelnut
Number of subjects: 151
Study: 20179669

Group type: EXPERIMENTAL
Intervention: Metformin (1 g per day) plus dietary treatment
Number of subjects: 50

Group type: COMPARATOR
Intervention: Dietary treatment alone
Number of subjects: 50
Study: 17920338

Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg 3 times a day for 6 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 15704047

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg twice daily
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg twice daily plus omeprazole 20 mg once daily
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 12842242

Group type: EXPERIMENTAL
Intervention: Eplerenone 25 mg once daily
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Eplerenone 50 mg once daily
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Eplerenone 100 mg once daily
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Eplerenone 200 mg once daily
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study: 12579651

Group type: EXPERIMENTAL
Intervention: Alomide eyedrops
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sodium cromoglycate eyedrops
Number of subjects: 0
Study: 8885731

Group type: EXPERIMENTAL
Intervention: Oral terbutaline (5 mg orally, every 4 hours)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Oral terbutaline
Number of subjects: 203
Study: 1676245

Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 12
Study: 6360923

Group type: EXPERIMENTAL
Intervention: Evening Primrose Oil (EPO)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 31884078

Group type: EXPERIMENTAL
Intervention: Text message link to online survey
Number of subjects: 110
Study: 30677788

Group type: EXPERIMENTAL
Intervention: LY2928057 600 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LY3113593 150 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: LY2928057
Number of subjects: 0

Group type: COMPARATOR
Intervention: LY3113593
Number of subjects: 0
Study: 28070770

Group type: EXPERIMENTAL
Intervention: Immediate dance intervention (10 private weekly dance lessons and 2 practice parties over 12 weeks)
Number of subjects: 31
Study: 27245158

Group type: EXPERIMENTAL
Intervention: Getting To Outcomes (GTO) implementation support intervention
Number of subjects: 32

Group type: COMPARATOR
Intervention: Making Proud Choices (MPC) control group
Number of subjects: 32
Study: 23819494

Group type: EXPERIMENTAL
Intervention: Conventional per-beam IMRT QA with gantry angle of 0
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional per-beam IMRT QA with gantry at specific angles
Number of subjects: 10
Study: 22006197

Group type: EXPERIMENTAL
Intervention: Mobile Bearing (MB) TKA
Number of subjects: 416

Group type: COMPARATOR
Intervention: Fixed Bearing (FB) TKA
Number of subjects: 416
Study: 19710342

Group type: EXPERIMENTAL
Intervention: Female partners of circumcised men; 11 out of 15 (73.3%) had ulcers due to HSV-2 or other pathogens.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Female partners of uncircumcised men; 15 out of 25 (60.0%) had ulcers due to HSV-2 or other pathogens.
Number of subjects: 40
Study: 17924278

Group type: EXPERIMENTAL
Intervention: Spoken output
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Written responding
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low output interference
Number of subjects: 0

Group type: COMPARATOR
Intervention: High output interference
Number of subjects: 0
Study: 15141930

Group type: EXPERIMENTAL
Intervention: Positive peer recommendations
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Negative peer recommendations
Number of subjects: 94

Group type: COMPARATOR
Intervention: Anticipation of providing evaluations
Number of subjects: 94
Study: 12597061

Group type: EXPERIMENTAL
Intervention: Fondaparinux (2.5 mg once daily, subcutaneous, starting postoperatively)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enoxaparin (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fondaparinux and Enoxaparin
Number of subjects: 0
Study: 10569656

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) levels
Number of subjects: 1172
Study: 8913184

Group type: EXPERIMENTAL
Intervention: Medical antireflux therapy (ranitidine plus cisapride)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 1991415

Group type: EXPERIMENTAL
Intervention: 7.5 percent semisolid gel
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Overall percent evacuation of three stool consistencies after IPAA
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Liquid stool consistency
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: IPAA group
Number of subjects: 24
Study: 6856646

Group type: EXPERIMENTAL
Intervention: Cocaine (16 mg, 32 mg, 48 mg)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Procaine (48 mg, 96 mg)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 4
Study: 31297968

Group type: EXPERIMENTAL
Intervention: Linagliptin 5 mg qd
Number of subjects: 302

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study: 29578090

Group type: EXPERIMENTAL
Intervention: Adjunctive internet cognitive‐behavioral therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adjunctive internet education
Number of subjects: 0
Study: 27488327

Group type: EXPERIMENTAL
Intervention: Vitamin D (300,000 IU intramuscular)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Normal saline (1 mL as placebo)
Number of subjects: 90
Study: 23791016

Group type: EXPERIMENTAL
Intervention: Structured withdrawal program (60 mcg/day for 15 days and then 60 mcg every second evening for another 15 days)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Abrupt withdrawal
Number of subjects: 81
Study: 24308282

Group type: EXPERIMENTAL
Intervention: Tailored intervention including training on medication management, provision of evidence-based checklists, a tablet PC with an interactive educational tool, and information leaflets for patients.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control practices providing care as usual without special training.
Number of subjects: 0
Study: 20495250

Group type: EXPERIMENTAL
Intervention: Titanium staples
Number of subjects: 12

Group type: COMPARATOR
Intervention: Mini-titanium plate with oblique screw
Number of subjects: 12
Study: 18832497

Group type: EXPERIMENTAL
Intervention: Second-generation antidepressants
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Active treatment (second-generation antidepressants)
Number of subjects: 27
Study: 16877896

Group type: EXPERIMENTAL
Intervention: Risperidone (4-6 mg/day)
Number of subjects: 757

Group type: COMPARATOR
Intervention: Conventional antipsychotics (haloperidol 10 or 20 mg/day, perphenazine mean dose 28 mg/day, zuclopenthixol mean dose 38 mg/day)
Number of subjects: 757

Group type: COMPARATOR
Intervention: Conventional antipsychotics
Number of subjects: 757
Study: 12512025

Group type: EXPERIMENTAL
Intervention: EP-1 antagonist ZD6416
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 12
Study: 11789207

Group type: EXPERIMENTAL
Intervention: Yimai Jiangya extract (YMJYE)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Captopril (control group)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Yimai Jiangya extract (YMJYE) and Captopril (control group)
Number of subjects: 42
Study: 9013269

Group type: EXPERIMENTAL
Intervention: Triglycerides
Number of subjects: 1726

Group type: EXPERIMENTAL
Intervention: Total cholesterol
Number of subjects: 1726

Group type: EXPERIMENTAL
Intervention: Lipid fractions
Number of subjects: 1726